Imatinib, a tyrosine kinase inhibitor of BCR-ABL in CML, can also bind to the BH3 domain of the Bcl-2 family member BIM (also known as BCL2L11), promoting its pro-apoptotic function (Kuroda et al., 2006). Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.